Therapeutics

HTG has evolved its platform technology

Advanced full transcriptome profiling combined with innovative medicinal chemistry, utilizing advanced data science structural and transcriptomic algorithms, is expected to enable more effective drug and companion diagnostic discovery across broad disease areas.

RNA Based Drugs and Diagnostics
 

  • Nervous System Disease
  • Cardiovascular
  • Diabetes
  • Infectious Disease
  • Immunology
  • Genetic Disease
  • Metabolic Disease
  • Liver Disease
  • Immuno-oncology
  • Rare Disease

We plan to use the HTG Transcriptome Panel and an epitranscriptome profiling technology evolved from the original HTG EdgeSeq technology (HTG EpiEdgeSeq) for the profiling of RNA modifications. By leveraging these profiling technologies earlier in the drug discovery process, HTG Therapeutics is seeking to generate lead compounds with superior efficacy and toxicity profiles. Having created a first-in-class transcriptomic and epitranscriptomic platform, HTG has implemented cutting edge medicinal chemistry in its therapeutic discovery efforts including multi-parameter computational filters and advanced structure, ligand and pharmacophore-based design. By pairing state-of-the-art expression profiling with innovative medicinal chemistry, HTG seeks to create the foundation for the future of drug discovery.

Four Pillars

The intersection of innovative profiling and chemistry

HTG EdgeSeq

Whole transcriptome mRNA and miRNA profiling guides drug discovery driving better understanding of health and disease.

HTG Chemistry Platform

Custom focus libraries, augmented chemo-informatics, multi-parameter computational filters, and advanced structure-based design.

 

HTG Epi-EdgeSeq

Epi transcriptome profiling assessing m6A, A-to-I and other RNA modifications.

HTG Informatics Platform

Iterative profiling and structural modifications are cycled to identify candidates with improved physiochemical properties.

Page last updated August 05, 2021